No abstract available.
Hemangioma* ; Injections, Intralesional* ; Propranolol ; Triamcinolone*

Author list should be corrected.

No abstract available.
Dapsone* ; Herpesvirus 4, Human* ; Hypersensitivity*

No abstract available.
Osteoma*

No abstract available.
Hypertrophy*

We evaluated the characteristics of HMB-45 monoclonal antibody(MoAb) and compared it with a polyclonal anti-S-100 antibody in immunohistochemical staining of 22 primary melanomas of the skin ; 13 acral lentiginous melanomas(ALM), 3 superficial spreading melanomas(SSM), 4 lentigo maligna melanomas(LMM), 3 nodular melanomas(NMM). All speimens were formalin-fixed and paraffin-embedded, and were studied with the avidin-biotin-peroxidase complex technique. The results can be summarized as follows : l. In all tissue specimens, all or some of the melanoma cells in the dermis reacted with HMB-45 MoAb and anti-S-100 protein. 2. HMB-45 MoAb is more sensitive in detecting malignant melanoma cell heterogeneity t,han anti-S-100 protein. 3. Melanoma cells within the epidermis in 6 of 12 ALMs and 3 of 4 LMMs did not react with anti-S-100 antibody, whereas most melanoma cells within epidermis of 12 ALMs and 4 LMMs reacted with HMB-45 monoclonal antibody. These results indicated that immunohistochemical staining with HMB-45 MoAb and anti-S-100 protein is very useful in the study of biologic behavior of malignant, melanoma.
Dermis ; Epidermis ; Hutchinson's Melanotic Freckle ; Melanoma* ; Population Characteristics ; Skin

The occurrence of an intramuscular mass accompanied by sleep-disturbing pain at the inoculation site lasting for 4 months after the coronavirus disease 2019 (COVID-19) vaccination is rare. A 68-year-old man, who had previously received multiple COVID-19 vaccinations without any issues, encountered the problem described above for the first time. After administering 200 mg of celecoxib and 10 mg of nortriptyline for 1 month, ultrasound assessment revealed that the mass volume was reduced by more than 50%, and the pain disappeared completely.

The occurrence of an intramuscular mass accompanied by sleep-disturbing pain at the inoculation site lasting for 4 months after the coronavirus disease 2019 (COVID-19) vaccination is rare. A 68-year-old man, who had previously received multiple COVID-19 vaccinations without any issues, encountered the problem described above for the first time. After administering 200 mg of celecoxib and 10 mg of nortriptyline for 1 month, ultrasound assessment revealed that the mass volume was reduced by more than 50%, and the pain disappeared completely.

The occurrence of an intramuscular mass accompanied by sleep-disturbing pain at the inoculation site lasting for 4 months after the coronavirus disease 2019 (COVID-19) vaccination is rare. A 68-year-old man, who had previously received multiple COVID-19 vaccinations without any issues, encountered the problem described above for the first time. After administering 200 mg of celecoxib and 10 mg of nortriptyline for 1 month, ultrasound assessment revealed that the mass volume was reduced by more than 50%, and the pain disappeared completely.

The occurrence of an intramuscular mass accompanied by sleep-disturbing pain at the inoculation site lasting for 4 months after the coronavirus disease 2019 (COVID-19) vaccination is rare. A 68-year-old man, who had previously received multiple COVID-19 vaccinations without any issues, encountered the problem described above for the first time. After administering 200 mg of celecoxib and 10 mg of nortriptyline for 1 month, ultrasound assessment revealed that the mass volume was reduced by more than 50%, and the pain disappeared completely.